If You Invested $1,000 in Gilead Sciences' IPO, This Is How Much Money You'd Have Now
Gilead Sciences (NASDAQ: GILD) has been in the news lately, with President Trump receiving doses of Gilead's experimental antiviral drug Veklury (remdesivir) earlier this month to help treat his coronavirus infection. It's already been an up-and-down year for Gilead -- in March, the stock hit a 52-week high of $85.97 on hopes that Veklury, originally tested to fight Ebola, would be the big answer to ending the coronavirus pandemic.
The stock slowly came down to earth, however, hurt by a May report in the New England Journal of Medicine that said Veklury only shortened the time of hospitalization by four days in COVID-19 patients, compared to a placebo.
Earlier in October, the stock was trading at about $62 a share, which -- while a long way from $85 -- is more than three times what it went for after its initial public offering (IPO) in January of 1992.
Source Fool.com
